In:
Immunotherapy, Future Medicine Ltd, Vol. 15, No. 13 ( 2023-09), p. 1029-1044
Abstract:
Plain language summary This analysis evaluated outcomes for East Asian patients with a type of advanced lung cancer which does not express a protein called programmed cell death ligand 1 (PD-L1). The patients received either an immunotherapy, called pembrolizumab, in combination with chemotherapy or chemotherapy alone. Overall survival (how long people live) and progression-free survival (how long people live without their disease getting worse) were longer for patients who received treatment with pembrolizumab plus chemotherapy versus those who received chemotherapy alone. Side effects among East Asian patients were similar to those previously described for a global patient population. These results support the use of pembrolizumab in combination with chemotherapy for East Asian patients with lung cancer that does not express PD-L1. Clinical Trial Registration: NCT02039674 ; NCT02578680 ; NCT03950674 ; NCT02775435 ; NCT03875092 ( ClinicalTrials.gov )
Type of Medium:
Online Resource
ISSN:
1750-743X
,
1750-7448
DOI:
10.2217/imt-2023-0043
Language:
English
Publisher:
Future Medicine Ltd
Publication Date:
2023